Literature DB >> 18307623

Are nonsustained ventricular tachycardias predictive of major arrhythmias in patients with dilated cardiomyopathy on optimal medical treatment?

Massimo Zecchin1, Andrea Di Lenarda, Dario Gregori, Marco Merlo, Alberto Pivetta, Giancarlo Vitrella, Gastone Sabbadini, Luisa Mestroni, Gianfranco Sinagra.   

Abstract

BACKGROUND: To evaluate the role of nonsustained ventricular tachycardias (NSVT) for the prediction of major ventricular arrhythmias (MVA) in patients with idiopathic dilated cardiomyopathy (DCM) after optimization of medical treatment. METHODS AND
RESULTS: Three hundred nineteen consecutive DCM patients were evaluated after adequate stabilization on optimal angiotensin-converting enzyme (ACE) inhibitor (88%) and beta-blocker (82%) therapy. Frequency, length, and rate of NSVT at 24-hour Holter monitoring were analyzed to assess their values in predicting MVA (unexpected sudden death, SVT, ventricular fibrillation, and appropriate implantable cardioverter defibrillator interventions). During follow-up (median 96 months, 1(st)-3(rd) interquartile range 52-130), MVA incidence was low, and not statistically different between patients with and without NSVT (3 and 2 per 100 patient-years, respectively, P = nonsignificant [NS] at log-rank analysis). At multivariable analysis, the number of NSVT was predictive of MVA only if left ventricular ejection fraction (LVEF) was > 0.35 (two NSVT/day vs no NSVT/day: hazard ratio [HR] 5.3, 95% confidence interval [CI] 1.59-17.85 in LVEF > 0.35 vs HR 0.93, 95% CI 0.3-2.81 in LVEF < or = 0.35). Consequently, in patients with LVEF < or = 0.35, MVA incidence rates were similar regardless of NSVT (3.6 and 4.1 patient-years, respectively, in those with and without NSVT, P = NS), while in patients with LVEF > 0.35, MVA incidence (3.1 per 100 patient-years vs 0.9 per 100 patient-years, P = 0.003) was significantly higher when NSVT were present.
CONCLUSIONS: After medical stabilization, NSVT did not increase the risk of MVA in patients with DCM and LVEF < or = 0.35. Conversely, the number and length of NSVT runs were significantly related to the occurrence of MVA in the patients with LVEF > 0.35.

Entities:  

Mesh:

Year:  2008        PMID: 18307623     DOI: 10.1111/j.1540-8159.2008.00988.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  9 in total

Review 1.  Dilated cardiomyopathy.

Authors:  Neal K Lakdawala; Jeffery R Winterfield; Birgit H Funke
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-09-28

2.  [Risk stratification of sudden cardiac death in dilated cardiomyopathy. Programmed ventricular stimulation].

Authors:  Dietmar Bänsch
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-02-19

3.  Diagnosis, prevalence, and screening of familial dilated cardiomyopathy.

Authors:  Mary Sweet; Matthew R G Taylor; Luisa Mestroni
Journal:  Expert Opin Orphan Drugs       Date:  2015-06-22       Impact factor: 0.694

4.  Arrhythmogenic Phenotype in Dilated Cardiomyopathy: Natural History and Predictors of Life-Threatening Arrhythmias.

Authors:  Anita Spezzacatene; Gianfranco Sinagra; Marco Merlo; Giulia Barbati; Sharon L Graw; Francesca Brun; Dobromir Slavov; Andrea Di Lenarda; Ernesto E Salcedo; Jeffrey A Towbin; Jeffrey E Saffitz; Frank I Marcus; Wojciech Zareba; Matthew R G Taylor; Luisa Mestroni
Journal:  J Am Heart Assoc       Date:  2015-10-16       Impact factor: 5.501

5.  Prognostic significance of nonsustained ventricular tachycardia in patients receiving cardiac resynchronization therapy for primary prevention: Analysis of the Japan cardiac device treatment registry database.

Authors:  Hisashi Yokoshiki; Akihiko Shimizu; Takeshi Mitsuhashi; Hiroshi Furushima; Yukio Sekiguchi; Tetsuyuki Manaka; Nobuhiro Nishii; Takeshi Ueyama; Norishige Morita; Hideo Okamura; Takashi Nitta; Kenzo Hirao; Ken Okumura
Journal:  J Arrhythm       Date:  2018-01-12

Review 6.  Sudden Cardiac Death Prediction in Non-ischemic Dilated Cardiomyopathy: a Multiparametric and Dynamic Approach.

Authors:  Daniel J Hammersley; Brian P Halliday
Journal:  Curr Cardiol Rep       Date:  2020-07-09       Impact factor: 2.931

Review 7.  Risk Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update.

Authors:  Daniele Masarone; Giuseppe Limongelli; Ernesto Ammendola; Marina Verrengia; Rita Gravino; Giuseppe Pacileo
Journal:  J Clin Med       Date:  2018-11-10       Impact factor: 4.241

Review 8.  Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy.

Authors:  M Akhtar; P M Elliott
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 9.  CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy.

Authors:  Laura Keil; Céleste Chevalier; Paulus Kirchhof; Stefan Blankenberg; Gunnar Lund; Kai Müllerleile; Christina Magnussen
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.